Although several versions of imaging-response standards related to the PD1/PD-L1 inhibitor have been explored to shrink the impact of AR patterns with regard to tumor-response evaluation [6,7], real-world clinical descriptions of this immune-related response pattern and treatment strategy in NSCLC remain scarce. The gene discussed is CD274; the disease is neoplasm.